Dyspnea — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for dyspnea. 70 active patents protecting 1 drugs from 1+ originators. First major cliff: 2026. Daily refresh.

1
Approved drugs
70
Active US patents
61/100
Avg vulnerability
—
Annual revenue covered

Originators in Dyspnea

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Pfizer Inc. 70 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating dyspnea. Each bar = one year. Y-axis scaled to peak year (32 patents).

3
26
3
27
6
28
6
29
7
35
2
36
6
37
4
38
32
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Epipen
epinephrine
 Pfizer Inc. 70 61 — 2026-12-12

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11173209 Epipen method of use 75 2038-02-06
11173209 Epipen method of use 75 2038-02-06
11744895 Epipen method of use 75 2039-02-06
11918655 Epipen method of use 75 2039-02-06
11744895 Epipen method of use 75 2039-02-06
11717571 Epipen method of use 75 2039-02-06
10682414 Epipen method of use 75 2039-02-06
11717571 Epipen method of use 75 2039-02-06
11191838 Epipen method of use 75 2039-02-06
11191838 Epipen method of use 75 2039-02-06

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9119876 Epipen formulation 42 2035-03-13
10130592 Epipen formulation 42 2035-03-13
9119876 Epipen formulation 42 2035-03-13
8021344 Epipen formulation 48 2029-11-02
10653646 Epipen formulation 50 2039-03-21
11207280 Epipen formulation 50 2039-03-21
10653646 Epipen formulation 50 2039-03-21
11207280 Epipen formulation 50 2039-03-21
11207280 Epipen formulation 50 2039-03-21
11207280 Epipen formulation 50 2039-03-21

Related